Pathophysiology of Meningiomas

ABSTRACT

This article provides a brief description of the current knowledge of meningioma tumorigenesis and biology. Meningioma grade, subtyping, histology, and MIB-1 labeling index are discussed in relationship to tumor behavior and recurrence prediction. Chromosomal abnormalities associated with meningioma development are discussed with an emphasis on chromosome 22 and the neurofibromatosis type 2 gene. The current knowledge of prognostic features of 1p deletions is outlined. The role of sex hormones in meningioma growth and development is also discussed and summarized. To date, treatment regimens based on inhibiting hormonally mediated meningioma growth have been disappointing. Research concerning growth factors and peptide hormones that have been implicated in meningioma tumorigenesis is discussed. It is hoped that further understanding of the biology of meningioma development, growth, and angiogenesis will lead to new successful treatments for refractory meningiomas.

KEYWORDS

Meningioma tumorigenesis - tumor grading - histology - prognosis

REFERENCES

• 1 Al-Rodhan R F, Laws E R. The history of intracranial meningiomas. In: Al-Mefty O, ed. Meningiomas New York: Raven Press 1991: 1-6
• 2 Carroll R S, Zhang J, Black P M. Expression of estrogen receptors alpha and beta in human meningiomas.  J Neurooncol . 1999;  42 109-116
• 3 Catala M. Embryonic and fetal development of structures associated with the cerebro-spinal fluid in man and other species. Part I: The ventricular system, meninges and choroid plexuses.  Arch Anat Cytol Pathol . 1998;  46 153-169
• 4 Burger P C, Scheithauer B W, Vogel F S. Surgical Pathology of the Nervous System and Its Coverings 4th ed.  Philadelphia: Churchill Livingstone; 2002: 49-71
• 5 Osborn A G. Diagnostic Neuroradiology.  St. Louis: Mosby 1994: 584-601
• 6 Mahmood A, Caccamo D V, Tomecek F J, Malik G M. Atypical and malignant meningiomas: a clinicopathological review.  Neurosurgery . 1993;  33 955-963
• 7 Gonzales M F. Classification of brain tumors. In: Kaye AH, Laws ER, eds. Brain Tumors 1st ed: Edinburgh: Churchill Livingstone 1995: 675
• 8 Louis D N, Scheithauer B W, Budka H, von Deimling A, Kepes J J. Meningiomas. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours: Pathology and Genetics: Tumours of the Nervous System Lyon: IARC Press; 2000: 175-189
• 9 Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome.  Surg Neurol . 1986;  25 233-242
• 10 Nakasu S, Li D H, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods.  Am J Surg Pathol . 2001;  25 472-478
• 11 Ho D M, Hsu C Y, Ting L T, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.  Cancer . 2002;  94 1538-1547
• 12 Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.  Pathol Res Pract . 2000;  196 483-488
• 13 Korshunov A, Shishkina L, Golanov A. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance.  Arch Pathol Lab Med . 2002;  126 1079-1086
• 14 Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/ CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas.  J Neurooncol . 2000;  46 205-213
• 15 Abramovich C M, Prayson R A. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.  Am J Clin Pathol . 2000;  114 84-92
• 16 Bostrom J, Meyer-Puttlitz B, Wolter M. et al . Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.  Am J Pathol . 2001;  159 661-669
• 17 Comtesse N, Heckel D, Racz A, Brass N, Glass B, Meese E. Five novel immunogenic antigens in meningioma: cloning, expression analysis, and chromosomal mapping.  Clin Cancer Res . 1999;  5 3560-3568
• 18 Weisberg S, Ashkenazi E, Israel Z. et al . Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation.  Am J Pathol . 2001;  159 1193-1197
• 19 Kilic T, Bayri Y, Ozduman K. et al . Tenascin in meningioma: expression is correlated with anaplasia, vascular endothelial growth factor expression, and peritumoral edema but not with tumor border shape.  Neurosurgery . 2002;  51 183-193
• 20 Griffin C A, Hruban R H, Long P P. et al . Chromosome abnormalities in meningeal neoplasms: do they correlate with histology?.  Cancer Genet Cytogenet . 1994;  78 46-52
• 21 Bolger G B, Stamberg J, Kirsch I R, Hollis G F, Schwarz D F, Thomas G H. Chromosome translocation t(14;22) and oncogene (c-sis) variant in a pedigree with familial meningioma.  N Engl J Med . 1985;  312 564-567
• 22 Awad I A, Kalfas I, Hahn J F, Little J R. Intracranial meningiomas in the aged: surgical outcome in the era of computed tomography.  Neurosurgery . 1989;  24 557-560
• 23 Cogen P H, Daneshvar L, Bowcock A M, Metzger A K, Cavalli-Sforza L L. Loss of heterozygosity for chromosome 22 DNA sequences in human meningioma.  Cancer Genet Cytogenet . 1991;  53 271-277
• 24 Casalone R, Minelli E, Granata P, Giudici A. Pseudodicentric isochromosome(22) in meningiomas.  Cancer Genet Cytogenet . 1990;  45 273-275
• 25 Dumanski J P, Carlbom E, Collins V P, Nordenskjold M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma.  Proc Natl Acad Sci U S A . 1987;  84 9275-9279
• 26 Lekanne Deprez H R, Riegman P H, van Drunen E. et al . Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas.  J Neuropathol Exp Neurol . 1995;  54 224-235
• 27 Meese E, Blin N, Zang K D. Loss of heterozygosity and the origin of meningioma.  Hum Genet . 1987;  77 349-351
• 28 Seizinger B R, de la Monte S, Atkins L, Gusella J F, Martuza R L. Molecular genetic approach to human meningioma: loss of genes on chromosome 22.  Proc Natl Acad Sci U S A . 1987;  84 5419-5423
• 29 Zang K D, Singer H. Chromosomal constitution of meningiomas.  Nature . 1967;  216 84-85
• 30 Zankl H, Zang K D. Correlations between clinical and cytogenetical data in 180 human meningiomas.  Cancer Genet Cytogenet . 1980;  1 351-356
• 31 Zang K D. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases.  Cytogenet Cell Genet . 2001;  93 207-220
• 32 Lekanne Deprez H R, Bianchi A B, Groen N A. et al . Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.  Am J Hum Genet . 1994;  54 1022-1029
• 33 Leon S P, Zhu J, Black P M. Genetic aberrations in human brain tumors.  Neurosurgery . 1994;  34 708-722
• 34 Bigner S H, Mark J, Bigner D D. Cytogenetics of human brain tumors.  Cancer Genet Cytogenet . 1990;  47 141-154
• 35 Wolff R K, Frazer K A, Jackler R K, Lanser M J, Pitts L H, Cox D R. Analysis of chromosome 22 deletions in neurofibromatosis type 2-related tumors.  Am J Hum Genet . 1992;  51 478-485
• 36 Merel P, Hoang-Xuan K, Sanson M. et al . Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas.  Genes Chromosomes Cancer . 1995;  13 211-216
• 37 Papi L, De Vitis R L, Vitelli F. et al . Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas.  Hum Genet . 1995;  95 347-351
• 38 Ng H K, Lau K M, Tse J Y. et al . Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.  Neurosurgery . 1995;  37 764-773
• 39 Wellenreuther R, Kraus J A, Lenartz D. et al . Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.  Am J Pathol . 1995;  146 827-832
• 40 Ikeda K, Saeki Y, Gonzalez-Agosti C, Ramesh V, Chiocca E A. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.  J Neurosurg . 1999;  91 85-92
• 41 Dirven C M, Grill J, Lamfers M L. et al . Gene therapy for meningioma: improved gene delivery with targeted adenoviruses.  J Neurosurg . 2002;  97 441-449
• 42 Lee J H, Sundaram V, Stein D J, Kinney S E, Stacey D W, Golubi M. Reduced expression of schwannomin/merlin in human sporadic meningiomas.  Neurosurgery . 1997;  40 578-587
• 43 Kalamarides M, Niwa-Kawakita M, Leblois H. et al . Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.  Genes Dev . 2002;  16 1060-1065
• 44 Akagi K, Kurahashi H, Arita N. et al . Deletion mapping of the long arm of chromosome 22 in human meningiomas.  Int J Cancer . 1995;  60 178-182
• 45 Lekanne Deprez H R, Groen N A, van Biezen A N. et al . A t(4;22) in a meningioma points to the localization of a putative tumor-suppressor gene.  Am J Hum Genet . 1991;  48 783-790
• 46 Lekanne Deprez H R, Groen N A, Louz D. et al . Constitutional DNA-level aberrations in chromosome 22 in a patient with multiple meningiomas.  Genes Chromosomes Cancer . 1994;  9 124-128
• 47 Dumanski J P, Rouleau G A, Nordenskjold M, Collins V P. Molecular genetic analysis of chromosome 22 in 81 cases of meningioma.  Cancer Res . 1990;  50 5863-5867
• 48 Pulst S M, Rouleau G A, Marineau C, Fain P, Sieb J P. Familial meningioma is not allelic to neurofibromatosis 2.  Neurology . 1993;  43 2096-2098
• 49 Schneider G, Lutz S, Henn W, Zang K D, Blin N. Search for putative suppressor genes in meningioma: significance of chromosome 22.  Hum Genet . 1992;  88 579-582
• 50 Ruttledge M H, Sarrazin J, Rangaratnam S. et al . Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.  Nat Genet . 1994;  6 180-184
• 51 Ruttledge M H, Xie Y G, Han F Y. et al . Deletions on chromosome 22 in sporadic meningioma.  Genes Chromosomes Cancer . 1994;  10 122-130
• 52 Bello M J, de Campos M J, Kusak M E. et al . Allelic loss at 1p is associated with tumor progression of meningiomas.  Genes Chromosomes Cancer . 1994;  9 296-298
• 53 Steudel W I, Feld R, Henn W, Zang K D. Correlation between cytogenetic and clinical findings in 215 human meningiomas.  Arch Neurochir Suppl (Wien) . 1996;  65 73-76
• 54 Muller P, Henn W, Niedermayer I. et al . Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas.  Clin Cancer Res . 1999;  5 3569-3577
• 55 Henn W, Cremerius U, Heide G. et al . Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas.  Cancer Genet Cytogenet . 1995;  79 144-148
• 56 Ketter R, Henn W, Niedermayer I. et al . Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases.  J Neurosurg . 2001;  95 601-607
• 57 Cai D X, Banerjee R, Scheithauer B W, Lohse C M, Kleinschmidt-Demasters B K, Perry A. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications.  J Neuropathol Exp Neurol . 2001;  60 628-636
• 58 Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, Barcia-Salorio J L, Llombart-Bosch A. Loss of 1p in recurrent meningiomas. A comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization.  Cancer Genet Cytogenet . 2001;  125 119-124
• 59 Simon M, von Deimling A, Larson J J. et al . Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression.  Cancer Res . 1995;  55 4696-4701
• 60 Schneider B F, Shashi V, von Kap-herr C, Golden W L. Loss of chromosomes 22 and 14 in the malignant progression of meningiomas. A comparative study of fluorescence in situ hybridization (FISH) and standard cytogenetic analysis.  Cancer Genet Cytogenet . 1995;  85 101-104
• 61 Perry A, Cai D X, Scheithauer B W. et al . Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases.  J Neuropathol Exp Neurol . 2000;  59 872-879
• 62 Gutmann D H, Donahoe J, Perry A. et al . Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.  Hum Mol Genet . 2000;  9 1495-1500
• 63 Prempree T, Amornmarn R, Faillace W J, Arce C A, Nguyen T Q. 1;19 translocation in human meningioma.  Cancer . 1993;  71 2306-2311
• 64 Vagner Capodano M A, Grisoli F, Gambarelli D, Sedan R, Pellet W, De Victor B. Correlation between cytogenetic and histopathological findings in 75 human meningiomas.  Neurosurgery . 1993;  32 892-900
• 65 Al Saadi A, Latimer F, Madercic M, Robbins T. Cytogenetic studies of human brain tumors and their clinical significance. II. Meningioma.  Cancer Genet Cytogenet . 1987;  26 127-141
• 66 Katsuyama J, Papenhausen P R, Herz F, Gazivoda P, Hirano A, Koss L G. Chromosome abnormalities in meningiomas.  Cancer Genet Cytogenet . 1986;  22 63-68
• 67 Westphal M, Hansel M, Kunzmann R, Holzel F, Herrmann H D. Spectrum of karyotypic aberrations in cultured human meningiomas.  Cytogenet Cell Genet . 1989;  52 45-49
• 68 Bigner S H, Wong A J, Mark J. et al . Relationship between gene amplification and chromosomal deviations in malignant human gliomas.  Cancer Genet Cytogenet . 1987;  29 165-170
• 69 Mark J. Chromosomal abnormalities and their specificity in human neoplasms: an assessment of recent observations by banding techniques.  Adv Cancer Res . 1977;  24 165-222
• 70 Lopez-Gines C, Cerda-Nicolas M, Barcia-Salorio J L, Llombart-Bosch A. Cytogenetical findings of recurrent meningiomas. A study of 10 tumors.  Cancer Genet Cytogenet . 1995;  85 113-117
• 71 Pykett M J, Murphy M, Harnish P R, George D L. Identification of a microsatellite instability phenotype in meningiomas.  Cancer Res . 1994;  54 6340-6343
• 72 Cushing J, Eisenhardt L. Meningiomas arising from the tuberculum sella.  Arch Ophthalmol . 1929;  1 1-41
• 73 Bickerstaff E R, Small J M, Guest I A. The relapsing course of certain meningiomas in relation to pregnancy and menstruation.  J Neurochem . 1958;  21 89-91
• 74 Goldstein P J, Rosenberg S, Smith R W. Maternal death and brain tumor: case report.  Am J Obstet Gynecol . 1972;  112 297-298
• 75 Hagedoorne A. The chiasmal syndrome and retrobulbar neuritis in pregnancy.  Am J Ophthalmol . 1937;  20 690-699
• 76 Weyand A S, Villemure J, Kelly P A. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas.  Cancer Res . 1986;  46 2545-2550
• 77 Mehta D, Khatib R, Patel S. Carcinoma of the breast and meningioma. Association and management.  Cancer . 1983;  51 1937-1940
• 78 Schoenberg B S, Christine B W, Whisnant J P. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer.  Neurology . 1975;  25 705-712
• 79 Bellur S N, Chandra V, Anderson R J. Association of meningiomas with obesity.  Ann Neurol . 1983;  13 346-347
• 80 Donnell M S, Meyer G A, Donegan W L. Estrogen-receptor protein in intracranial meningiomas.  J Neurosurg . 1979;  50 499-502
• 81 Magdelenat H, Pertuiset B F, Poisson M. et al . Progestin and oestrogen receptors in meningiomas. Biochemical characterization, clinical and pathological correlations in 42 cases.  Acta Neurochir (Wien) . 1982;  64 199-213
• 82 Martuza R L, Miller D C, MacLaughlin D T. Estrogen and progestin binding by cytosolic and nuclear fractions of human meningiomas.  J Neurosurg . 1985;  62 750-756
• 83 Poisson M. Sex steroid receptors in human meningiomas.  Clin Neuropharmacol . 1984;  7 320-324
• 84 Tilzer L L, Plapp F V, Evans J P, Stone D, Alward K. Steroid receptor proteins in human meningiomas.  Cancer . 1982;  49 633-636
• 85 Markwalder T M, Zava D T, Goldhirsch A, Markwalder R V. Estrogen and progesterone receptors in meningiomas in relation to clinical and pathologic features.  Surg Neurol . 1983;  20 42-47
• 86 Piantelli M, Rinelli A, Macri E. et al . Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas.  Cancer . 1993;  71 193-198
• 87 Blankenstein M A, Blaauw G, Lamberts S W. Progestin and estrogen receptors in human meningioma.  Clin Neuropharmacol . 1984;  7 363-367
• 88 Moguilewsky M, Pertuiset B F, Verzat C, Philibert D, Philippon J, Poisson M. Cytosolic and nuclear sex steroid receptors in meningioma.  Clin Neuropharmacol . 1984;  7 375-381
• 89 Hayward E, Whitwell H, Paul K S, Barnes D M. Steroid receptors in human meningioma.  Clin Neuropharmacol . 1984;  7 351-356
• 90 Cahill D W, Bashirelahi N, Solomon L W, Dalton T, Salcman M, Ducker T B. Estrogen and progesterone receptors in meningiomas.  J Neurosurg . 1984;  60 985-993
• 91 Courriere P, Tremoulet M, Eche N, Armand J P. Hormonal steroid receptors in intracranial tumours and their relevance in hormone therapy.  Eur J Cancer Clin Oncol . 1985;  21 711-714
• 92 Blaauw G, Blankenstein M A, Lamberts S W. Sex steroid receptors in human meningiomas.  Acta Neurochir (Wien) . 1986;  79 42-47
• 93 Blankenstein M A, van der Meulen-Dijk C, Thijssen J H. Assay of oestrogen and progestin receptors in human meningioma cytosols using immunological methods.  Clin Chim Acta . 1987;  165 189-195
• 94 Benzel E C, Gelder F B. Correlation between sex hormone binding and peritumoral edema in intracranial meningiomas.  Neurosurgery . 1988;  23 169-174
• 95 Koehorst S G, Jacobs H M, Tilanus M G, Bouwens A G, Thijssen J H, Blankenstein M A. Aberrant oestrogen receptor species in human meningioma tissue.  J Steroid Biochem Mol Biol . 1992;  43 57-61
• 96 Brandis A, Mirzai S, Tatagiba M, Walter G F, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features.  Neurosurgery . 1993;  33 212-218
• 97 Carroll R S, Glowacka D, Dashner K, Black P M. Progesterone receptor expression in meningiomas.  Cancer Res . 1993;  53 1312-1316
• 98 Ironside J W, Battersby R D, Dangerfield V J, Parsons M A, Timperley W R, Underwood J C. Cryostat section assay of oestrogen and progesterone receptors in meningiomas: a clinicopathological study.  J Clin Pathol . 1986;  39 44-50
• 99 Lesch K P, Fahlbusch R. Simultaneous estradiol and progesterone receptor analysis in meningiomas.  Surg Neurol . 1986;  26 257-263
• 100 Lesch K P, Engl H G, Gross S. Androgen receptor binding activity in meningiomas.  Surg Neurol . 1987;  28 176-180
• 101 Lesch K P, Engl H G, Schott W, Gross S. Immunoreactive estrogen receptor protein in meningiomas: comparison with the androgen receptor and progesterone receptor binding activity.  Zentralbl Neurochir . 1987;  48 124-134
• 102 Schrell U M, Adams E F, Fahlbusch R. et al . Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy.  J Neurosurg . 1990;  73 743-749
• 103 Piquer J, Cerda M, Lluch A, Barcia-Salorio J L, Garcia-Conde J. Correlations of female steroid hormone receptors with histologic features in meningiomas.  Acta Neurochir (Wien) . 1991;  110 38-43
• 104 Meixensberger J, Caffier H, Naumann M, Hofmann E. Sex hormone binding and peritumoural oedema in meningiomas: is there a correlation?.  Acta Neurochir (Wien) . 1992;  115 98-102
• 105 Perrot-Applanat M, Groyer-Picard M T, Kujas M. Immunocytochemical study of progesterone receptor in human meningioma.  Acta Neurochir (Wien) . 1992;  115 20-30
• 106 Maxwell M, Galanopoulos T, Neville-Golden J, Antoniades H N. Expression of androgen and progesterone receptors in primary human meningiomas.  J Neurosurg . 1993;  78 456-462
• 107 Verhagen A, Go K G, Visser G M, Blankenstein M A, Vaalburg W. The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: its relevance to expression of progesterone receptors in meningiomas.  Br J Neurosurg . 1995;  9 47-50
• 108 Bouillot P, Pellissier J F, Devictor B. et al . Quantitative imaging of estrogen and progesterone receptors, estrogen-regulated protein, and growth fraction: immunocytochemical assays in 52 meningiomas. Correlation with clinical and morphological data.  J Neurosurg . 1994;  81 765-773
• 109 Zava D T, Markwalder T M, Markwalder R V. Biological expression of steroid hormone receptors in primary meningioma cells in monolayer culture.  Clin Neuropharmacol . 1984;  7 382-388
• 110 Jay J R, MacLaughlin D T, Riley K R, Martuza R L. Modulation of meningioma cell growth by sex steroid hormones in vitro.  J Neurosurg . 1985;  62 757-762
• 111 Olson J J, Beck D W, Schlechte J, Loh P M. Hormonal manipulation of meningiomas in vitro.  J Neurosurg . 1986;  65 99-107
• 112 Weisman A S, Villemure J G, Kelly P A. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas.  Cancer Res . 1986;  46 2545-2550
• 113 Waelti E R, Markwalder T M. Endocrine manipulation of meningiomas with medroxyprogesterone acetate. Effect of MPA on growth of primary meningioma cells in monolayer tissue culture.  Surg Neurol . 1989;  31 96-100
• 114 Grunberg S M, Daniels A M, Muensch H. et al . Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay.  J Neurosurg . 1987;  66 405-408
• 115 Adams E F, Schrell U M, Fahlbusch R, Thierauf P. Hormonal dependency of cerebral meningiomas. Part 2: In vitro effect of steroids, bromocriptine, and epidermal growth factor on growth of meningiomas.  J Neurosurg . 1990;  73 750-755
• 116 Olson J J, Beck D W, Schlechte J A, Loh P M. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice.  J Neurosurg . 1987;  66 584-587
• 117 Koper J W, Foekens J A, Braakman R, Lamberts S W. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells.  Cancer Res . 1990;  50 2604-2607
• 118 Schrell U M, Nomikos P, Schrauzer T. et al . Hormonal dependency of cerebral meningiomas.  Acta Neurochir Suppl (Wien) . 1996;  65 54-57
• 119 Markwalder T M, Seiler R W. Chronic subdural hematomas: to drain or not to drain?.  Neurosurgery . 1985;  16 185-188
• 120 Goodwin J W, Crowley J, Eyre H J, Stafford B, Jaeckle K A, Townsend J J. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.  J Neurooncol . 1993;  15 75-77
• 121 Markwalder T M, Gerber H A, Waelti E, Schaffner T, Markwalder R V. Hormonotherapy of meningiomas with medroxyprogesterone acetate. Immunohistochemical demonstration of the effect of medroxyprogesterone acetate on growth fractions of meningioma cells using the monoclonal antibody Ki-67.  Surg Neurol . 1988;  30 97-101
• 122 Jaaskelainen J, Laasonen E, Karkkainen J, Haltia M, Troupp H. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases.  Acta Neurochir (Wien) . 1986;  80 35-41
• 123 Grunberg S M, Weiss M H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma.  J Neurooncol . 1990;  8 61-65
• 124 Grunberg S M, Weiss M H, Spitz I M. et al . Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone.  J Neurosurg . 1991;  74 861-866
• 125 Lamberts S W, Koper J W, de Jong H F. The endocrine effects of long-term treatment with mifepristone (RU 486).  J Clin Endocrinol Metab . 1991;  73 187-191
• 126 Lamberts S W, Koper J W, Reubi J C, Krenning E P. Endocrine aspects of the diagnosis and treatment of primary brain tumours.  Clin Endocrinol (Oxf) . 1992;  37 1-10
• 127 Sartor O, Figg W D. Mifepristone: antineoplastic studies.  Clin Obstet Gynecol . 1996;  39 498-505
• 128 Piper J G, Follett K A, Fantin A. Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant.  Neurosurgery . 1994;  34 723-725
• 129 Matsuda Y, Kawamoto K, Kiya K, Kurisu K, Sugiyama K, Uozumi T. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.  J Neurosurg . 1994;  80 527-534
• 130 Davis C. Surgical and non-surgical treatment of symptomatic intracranial meningiomas.  Br J Neurosurg . 1995;  9 295-302
• 131 Carroll R S, Schrell U M, Zhang J. et al . Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas.  Neurosurgery . 1996;  38 367-375
• 132 Jimenez-Hakim E, el Azouzi M, Black P M. The effect of prolactin and bombesin on the growth of meningioma-derived cells in monolayer culture.  J Neurooncol . 1993;  16 185-190
• 133 Boyle-Walsh E, Shenkin A, White M C, Fraser W D. Effect of glycoprotein and protein hormones on human meningioma cell proliferation in vitro.  J Endocrinol . 1995;  145 155-161
• 134 Smidt M, Kirsch I, Ratner L. Deletion of Alu sequences in the fifth c-sis intron in individuals with meningiomas.  J Clin Invest . 1990;  86 1151-1157
• 135 Kazumoto K, Tamura M, Hoshino H, Yuasa Y. Enhanced expression of the sis and c-myc oncogenes in human meningiomas.  J Neurosurg . 1990;  72 786-791
• 136 Carstens C, Messe E, Zang K D, Blin N. Human KRAS oncogene expression in meningioma.  Cancer Lett . 1988;  43 37-41
• 137 Diedrich U, Eckermann O, Schmidtke J. Rare Ha-ras and c-mos alleles in patients with intracranial tumors.  Neurology . 1988;  38 587-589
• 138 Detta A, Kenny B G, Smith C, Logan A, Hitchcock E. Correlation of proto-oncogene expression and proliferation and meningiomas.  Neurosurgery . 1993;  33 1065-1074
• 139 Wang G L, Jiang B H, Rue E A, Semenza G L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.  Proc Natl Acad Sci USA . 1995;  92 5510-5514
• 140 Zhao J F, Sharma S. Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas.  Cancer Genet Cytogenet . 1995;  83 148-154
• 141 Baugnet-Mahieu L, Lemaire M, Brotchi J. et al . Epidermal growth factor receptors in human tumors of the central nervous system.  Anticancer Res . 1990;  10 1275-1280
• 142 Grimaux M, Magdelenat H, Poisson M. et al . [EGF receptors (epidermal growth factor) and steroid receptors in human meningioma].  Rev Neurol (Paris) . 1988;  144 96-103
• 143 Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll B. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis.  J Neurol . 1995;  242 683-688
• 144 Torp S H, Helseth E, Dalen A, Unsgaard G. Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue.  APMIS . 1992;  100 797-802
• 145 Sanfilippo J S, Rao C V, Guarnaschelli J J. et al . Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings.  Surg Gynecol Obstet . 1993;  177 488-496
• 146 Linggood R M, Hsu D W, Efird J T, Pardo F S. TGF alpha expression in meningioma-tumor progression and therapeutic response.  J Neurooncol . 1995;  26 45-51
• 147 Westphal M, Herrmann H D. Epidermal growth factor-receptors on cultured human meningioma cells.  Acta Neurochir (Wien) . 1986;  83 62-66
• 148 Koper J W, Zwarthoff E C, Hagemeijer A. et al . Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha.  Eur J Cancer . 1991;  27 416-419
• 149 Di Carlo A, Mariano A, Macchia P E, Moroni M C, Beguinot L, Macchia V. Epidermal growth factor receptor in human brain tumors.  J Endocrinol Invest . 1992;  15 31-37
• 150 Kitagawa N, Tsutsumi K, Niwa M. et al . Expression of a functional endothelin (ETA) receptor in human meningiomas.  J Neurosurg . 1994;  80 723-731
• 151 Johnson M D, Horiba M, Winnier A R, Arteaga C L. The epidermal growth factor receptor is associated with phospholipase C-gamma 1 in meningiomas.  Hum Pathol . 1994;  25 146-153
• 152 Todo T, Fahlbusch R. Accumulation of inositol phosphates in low-passage human meningioma cells following treatment with epidermal growth factor.  J Neurosurg . 1994;  80 890-896
• 153 Carroll R S, Black P M, Zhang J. et al . Expression and activation of epidermal growth factor receptors in meningiomas.  J Neurosurg . 1997;  87 315-323
• 154 Wang J L, Nister M, Hermansson M, Westermark B, Ponten J. Expression of PDGF beta-receptors in human meningioma cells.  Int J Cancer . 1990;  46 772-778
• 155 Adams E F, Todo T, Schrell U M, Thierauf P, White M C, Fahlbusch R. Autocrine control of human meningioma proliferation: secretion of platelet-derived growth-factor-like molecules.  Int J Cancer . 1991;  49 398-402
• 156 Black P M, Carroll R, Glowacka D, Riley K, Dashner K. Platelet-derived growth factor expression and stimulation in human meningiomas.  J Neurosurg . 1994;  81 388-393
• 157 Johnson M D, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells.  J Neurosurg . 2001;  94 293-300
• 158 Figarella-Branger D, Vagner-Capodano A M, Bouillot P. et al . Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis.  Neuropathol Appl Neurobiol . 1994;  20 439-447
• 159 Maxwell M, Galanopoulos T, Hedley-Whyte E T, Black P M, Antoniades H N. Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products.  Int J Cancer . 1990;  46 16-21
• 160 Todo T, Adams E F, Fahlbusch R, Dingermann T, Werner H. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor.  J Neurosurg . 1996;  84 852-859
• 161 Schrell U M, Gauer S, Kiesewetter F. et al . Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.  J Neurosurg . 1995;  82 600-607
• 162 Todo T, Adams E F, Fahlbusch R. Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation.  J Neurosurg . 1993;  78 463-469
• 163 Jensen R L, Lee Y S, Guijrati M, Origitano T C, Wurster R D, Reichman O H. Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II. Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements.  Neurosurgery . 1995;  37 937-947
• 164 Jensen R L, Origitano T C, Lee Y S, Weber M, Wurster R D. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists.  Neurosurgery . 1995;  36 365-437
• 165 Jensen R L, Petr M, Wurster R D. Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation.  Neurosurgery . 2000;  46 692-703
• 166 Merry S, Fetherston C A, Kaye S B, Freshney R I, Plumb J A. Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.  Br J Cancer . 1986;  53 129-135
• 167 Jensen R L, Wurster R D. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice.  Surg Neurol . 2001;  55 275-283
• 168 Bowles A P, Pantazis C G, Wansley W. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.  J Neurosurg . 1990;  73 248-253
• 169 Cano-Gauci D F, Riordan J R. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation.  Biochem Pharmacol . 1987;  36 2115-2123
• 170 Helson L. Calcium channel blocker enhancement of anticancer drug cytotoxicity-a review.  Cancer Drug Deliv . 1984;  1 353-361
• 171 Ince P, Appleton D R, Finney K J, Sunter J P, Watson A J. Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine.  Br J Cancer . 1986;  53 137-139
• 172 Robinson B A, Clutterbuck R D, Millar J L, McElwain T J. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow.  Br J Cancer . 1985;  52 813-822
• 173 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.  Cancer Res . 1981;  41 1967-1972
• 174 Takahashi J A, Suzui H, Yasuda Y. et al . Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas.  Biochem Biophys Res Commun . 1991;  177 1-7
• 175 Takahashi J A, Mori H, Fukumoto M. et al . Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues.  Proc Natl Acad Sci USA . 1990;  87 5710-5714
• 176 Ueba T, Takahashi J A, Fukumoto M. et al . Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues.  Neurosurgery . 1994;  34 221-226
• 177 Paulus W, Grothe C, Sensenbrenner M. et al . Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors.  Acta Neuropathol (Berl) . 1990;  79 418-423
• 178 Brem S, Tsanaclis A M, Gately S, Gross J L, Herblin W F. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors.  Cancer . 1992;  70 2673-2680
• 179 Samoto K, Ikezaki K, Ono M. et al . Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors.  Cancer Res . 1995;  55 1189-1193
• 180 Antoniades H N, Galanopoulos T, Neville-Golden J, Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry.  Int J Cancer . 1992;  50 215-222
• 181 Glick R P, Gettleman R, Patel K, Lakshman R, Tsibris J C. Insulin and insulin-like growth factor I in brain tumors: binding and in vitro effects.  Neurosurgery . 1989;  24 791-797
• 182 Glick R P, Unterman T G, Van der Woude M, Blaydes L Z. Insulin and insulin-like growth factors in central nervous system tumors. Part V: Production of insulin-like growth factors I and II in vitro.  J Neurosurg . 1992;  77 445-450
• 183 Lichtor T, Kurpakus M A, Gurney M E. Expression of insulin-like growth factors and their receptors in human meningiomas.  J Neurooncol . 1993;  17 183-190
• 184 Kurihara M, Tokunaga Y, Tsutsumi K. et al . Characterization of insulin-like growth factor I and epidermal growth factor receptors in meningioma.  J Neurosurg . 1989;  71 538-544
• 185 Unterman T G, Glick R P, Waites G T, Bell S C. Production of insulin-like growth factor-binding proteins by human central nervous system tumors.  Cancer Res . 1991;  51 3030-3036
• 186 Friend K E. Cancer and the potential place for growth hormone receptor antagonist therapy.  Growth Horm IGF Res . 2001;  11 (suppl A) S121-S123
• 187 Tsutsumi K, Kitagawa N, Niwa M, Himeno A, Taniyama K, Shibata S. Effect of suramin on 125I-insulin-like growth factor-I binding to human meningiomas and on proliferation of meningioma cells.  J Neurosurg . 1994;  80 502-509
• 188 Lawrence J H, Tobias C A, Linfoot J A. et al . Successful treatment of acromegaly: metabolic and clinical studies in 145 patients.  J Clin Endocrinol Metab . 1970;  31 180-198
• 189 Khandwala H M, McCutcheon I E, Flyvbjerg A, Friend K E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.  Endocr Rev . 2000;  21 215-244
• 190 McCutcheon I E, Flyvbjerg A, Hill H. et al . Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.  J Neurosurg . 2001;  94 487-492
• 191 Trainer P J, Drake W M, Katznelson L. et al . Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.  N Engl J Med . 2000;  342 1171-1177
• 192 van der Lely J A, Hutson R K, Trainer P J. et al . Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.  Lancet . 2001;  358 1754-1759
• 193 Garcia-Luna P P, Relimpio F, Pumar A. et al . Clinical use of octreotide in unresectable meningiomas. A report of three cases.  J Neurosurg Sci . 1993;  37 237-241
• 194 Kunert-Radek J, Stepien H, Radek A, Lyson K, Pawlikowski M. Inhibitory effect of calcium channel blockers on proliferation of human glioma cells in vitro.  Acta Neurol Scand . 1989;  79 166-169
• 195 Huisman T W, Tanghe H L, Koper J W. et al . Progesterone, oestradiol, somatostatin and epidermal growth factor receptors on human meningiomas and their CT characteristics.  Eur J Cancer . 1991;  27 1453-1457
• 196 Reubi J C, Maurer R, von Werder K, Torhorst J, Klijn J G, Lamberts S W. Somatostatin receptors in human endocrine tumors.  Cancer Res . 1987;  47 551-558
• 197 Reubi J C, Horisberger U, Lang W, Koper J W, Braakman R, Lamberts S W. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors.  Am J Pathol . 1989;  134 337-344
• 198 Schulz S, Pauli S U, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A.  Clin Cancer Res . 2000;  6 1865-1874
• 199 Berkman R A, Merrill M J, Reinhold W C. et al . Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.  J Clin Invest . 1993;  91 153-159
• 200 Hatva E, Kaipainen A, Mentula P. et al . Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.  Am J Pathol . 1995;  146 368-378
• 201 Takano S, Yoshii Y, Kondo S. et al . Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients.  Cancer Res . 1996;  56 2185-2190
• 202 Goldman C K, Bharara S, Palmer C A. et al . Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression.  Neurosurgery . 1997;  40 1269-1277
• 203 Kalkanis S N, Carroll R S, Zhang J, Zamani A A, Black P M. Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas.  J Neurosurg . 1996;  85 1095-1101
• 204 Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A. Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.  Neurosurgery . 1997;  40 1016-1026
• 205 Lamszus K, Lengler U, Schmidt N O, Stavrou D, Ergun S, Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.  Neurosurgery . 2000;  46 938-948
• 206 Shono T, Inamura T, Torisu M, Suzuki S O, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: case report.  Neurol Res . 2000;  22 189-193
• 207 Dietzmann K, von Bossanyi P, Warich-Kirches M, Kirches E, Synowitz H J, Firsching R. Immunohistochemical detection of vascular growth factors in angiomatous and atypical meningiomas, as well as hemangiopericytomas.  Pathol Res Pract . 1997;  193 503-510
• 208 Nishikawa R, Cheng S Y, Nagashima R, Huang H J, Cavenee W K, Matsutani M. Expression of vascular endothelial growth factor in human brain tumors.  Acta Neuropathol (Berl) . 1998;  96 453-462
• 209 Pietsch T, Valter M M, Wolf H K. et al . Expression and distribution of vascular endothelial growth factor protein in human brain tumors.  Acta Neuropathol (Berl) . 1997;  93 109-117
• 210 Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas.  Cancer . 2000;  89 1102-1110
• 211 Bitzer M, Opitz H, Popp J. et al . Angiogenesis and brain oedema in intracranial meningiomas: influence of vascular endothelial growth factor.  Acta Neurochir (Wien) . 1998;  140 333-340
• 212 Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply.  Cancer . 1999;  85 936-944
• 213 Tsai J C, Hsiao Y Y, Teng L J. et al . Regulation of vascular endothelial growth factor secretion in human meningioma cells.  J Formos Med Assoc . 1999;  98 111-117
• 214 Forsythe J A, Jiang B H, Iyer N V. et al . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.  Mol Cell Biol . 1996;  16 4604-4613
• 215 Richard D E, Berra E, Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia.  Biochem Biophys Res Commun . 1999;  266 718-722
• 216 Jensen R L, Soleau S, Bhayani M K, Christiansen D. Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas.  J Neurosurg . 2002;  97 658-667
• 217 Pagotto U, Arzberger T, Hopfner U, Weindl A, Stalla G K. Cellular localization of endothelin receptor mRNAs (ETA and ETB) in brain tumors and normal human brain.  J Cardiovasc Pharmacol . 1995;  26 (suppl 3) S104-S106
• 218 Pagotto U, Arzberger T, Hopfner U. et al . Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth.  J Clin Invest . 1995;  96 2017-2025
• 219 Harland S P, Kuc R E, Pickard J D, Davenport A P. Characterization of endothelin receptors in human brain cortex, gliomas, and meningiomas.  J Cardiovasc Pharmacol . 1995;  26 (suppl 3) S408-S411
• 220 Yamaga S, Tsutsumi K, Niwa M. et al . Endothelin receptor in microvessels isolated from human meningiomas: quantification with radioluminography.  Cell Mol Neurobiol . 1995;  15 327-340
• 221 Bek E L, McMillen M A. Endothelins are angiogenic.  J Cardiovasc Pharmacol . 2000;  36 S135-S139
• 222 Harland S P, Kuc R E, Pickard J D, Davenport A P. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707.  Neurosurgery . 1998;  43 890-899
• 223 Nitta T, Sato K, Okumura K. Transforming growth factor (TGF)-beta like activity of intracranial meningioma and its effect on cell growth.  J Neurol Sci . 1991;  101 19-23
• 224 Merlo A, Juretic A, Zuber M. et al . Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns.  Eur J Cancer . 1993;  29A 2118-2125
• 225 Johnson M D, Federspiel C F, Gold L I, Moses H L. Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells.  Am J Pathol . 1992;  141 633-642
• 226 Johnson M D, Gold L I, Moses H L. Evidence for transforming growth factor-beta expression in human leptomeningeal cells and transforming growth factor-beta-like activity in human cerebrospinal fluid.  Lab Invest . 1992;  67 360-368
• 227 Johnson M D, Jennings M T, Gold L I, Moses H L. Transforming growth factor-beta in neural embryogenesis and neoplasia.  Hum Pathol . 1993;  24 457-462
• 228 Reubi J C, Lamberts S W, Palacios J M. Hormone dependency of meningiomas.  Lancet . 1989;  2 1099-1100
• 229 Schrell U M, Nomikos P, Fahlbusch R. Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue.  J Neurosurg . 1992;  77 288-294
• 230 Todo T, Adams E F, Rafferty B, Fahlbusch R, Dingermann T, Werner H. Secretion of interleukin-6 by human meningioma cells: possible autocrine inhibitory regulation of neoplastic cell growth.  J Neurosurg . 1994;  81 394-401
• 231 Levy E I, Paino J E, Sarin P S. et al . Enzyme-linked immunosorbent assay quantification of cytokine concentrations in human meningiomas.  Neurosurgery . 1996;  39 823-829
• 232 Boyle-Walsh E, Hashim I A, Speirs V, Fraser W D, White M C. Interleukin-6 (IL-6) production and cell growth of cultured human ameningiomas: interactions with interleukin-1 beta (IL-1 beta) and interleukin-4 (IL-4) in vitro.  Neurosci Lett . 1994;  170 129-132
• 233 Huttner A, Lei T, Fahlbusch R, Schrell W, Adams E F. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6.  Life Sci . 1996;  58 1323-1329
• 234 Folkman J, Ingber D. Inhibition of angiogenesis.  Semin Cancer Biol . 1992;  3 89-96
• 235 Kaba S E, DeMonte F, Bruner J M. et al . The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.  Neurosurgery . 1997;  40 271-275
• 236 Zhang Z J, Muhr C, Wang J L. Interferon-alpha inhibits the DNA synthesis induced by PDGF and EGF in cultured meningioma cells.  Anticancer Res. 16 717-723
• 237 Wober-Bingol C, Wober C, Marosi C, Prayer D. Interferon-alfa-2b for meningioma.  Lancet . 1995;  345 331
• 238 Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang Z J, Langstrom B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography.  Clin Cancer Res . 2001;  7 2269-2276
• 239 Gibelli N, Zibera C, Butti G. et al . Hormonal modulation of brain tumour growth: a cell culture study.  Acta Neurochir (Wien) . 1989;  101 129-133
• 240 Lee L S, Chi C W, Chang T J, Chou M D, Liu H C, Liu T Y. Steroid hormone receptors in meningiomas of Chinese patients.  Neurosurgery . 1989;  25 541-545
• 241 Yu Z Y, Wrange O, Boethius J, Hatam A, Granholm L, Gustafsson J A. A study of glucocorticoid receptors in intracranial tumors.  J Neurosurg . 1981;  55 757-760
• 242 Carroll R S, Zhang J, Dashner K, Sar M, Wilson E M, Black P M. Androgen receptor expression in meningiomas.  J Neurosurg . 1995;  82 453-460
• 243 Mailleux P, Przedborski S, Beaumont A. et al . Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas.  Peptides . 1990;  11 1245-1253
• 244 Przedborski S, Levivier M, Cadet J L. Neurotensin receptors in human meningiomas.  Ann Neurol . 1991;  30 650-654
• 245 Recht L, Torres C O, Smith T W, Raso V, Griffin T W. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy.  J Neurosurg . 1990;  72 941-945
• 246 Battaini F, Leggio A, Govoni S. et al . Decrease in phorbol ester receptors in human brain tumors.  Eur Neurol . 1990;  30 241-246
• 247 Rudling M J, Angelin B, Peterson C O, Collins V P. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement.  Cancer Res . 1990;  50 483-487
• 248 Sawaya R, Yamamoto M, Ramo O J, Shi M L, Rayford A, Rao J S. Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.  Neurosurgery . 1995;  36 375-381
• 249 Shinoura N, Heffelfinger S C, Miller M. et al . RNA expression of complement regulatory proteins in human brain tumors.  Cancer Lett . 1994;  86 143-149
• 250 Figarella-Branger D, Pellissier J F, Bouillot P. et al . Expression of neural cell-adhesion molecule isoforms and epithelial cadherin adhesion molecules in 47 human meningiomas: correlation with clinical and morphological data.  Mod Pathol . 1994;  7 752-761
• 251 Yamashima T, Sakuda K, Tohma Y. et al . Prostaglandin D synthase (beta-trace) in human arachnoid and meningioma cells: roles as a cell marker or in cerebrospinal fluid absorption, tumorigenesis, and calcification process.  J Neurosci . 1997;  17 2376-2382